CannaPharmaRx Inc
OTC:CPMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its 3-Year Average (4.9), the stock would be worth $-0 (100% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -7 656.5 | $0 |
0%
|
| 3-Year Average | 4.9 | $-0 |
-100%
|
| Industry Average | 15.5 | $-0 |
-100%
|
| Country Average | 22 | $-0 |
-100%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
|
CannaPharmaRx Inc
OTC:CPMD
|
2.3m USD | -7 656.5 | -0.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 65.4 | 42.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 21.2 | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 27.5 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 51.5 | 28 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 11.9 | 14.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 9.4 | 20.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -766.6 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 23.6 | 11.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 24.6 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 20.1 | 17.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.2 |
| Median | 22 |
| 70th Percentile | 36 |
| Max | 116 589.8 |
Other Multiples
CannaPharmaRx Inc
Glance View
CannaPharmaRx, Inc. engages in the research and manufacture of cannabinoid-based pharmaceuticals. The company is headquartered in Calgary, Alberta and currently employs 4 full-time employees. The principal activity of the Company is to negotiate, acquire and develop various cannabis cultivation projects throughout Canada. The firm's activities is centered around projects, such as the Great Northern Project, and the acquisition of Ramon Road Production Campus LLC. The firm is focused on producing wholesale cannabis and hemp for the medical market.
